#France #Barcelona #Biopharma #Servier #Veeva RIM

Servier Partners with Veeva RIM for Regulatory Transformation

In a strategic move to enhance its regulatory operations globally, Servier has announced its decision to adopt Veeva RIM, a platform designed to unify and streamline the regulatory processes of biopharmaceutical companies. This initiative, communicated by Veeva Systems, aims to accelerate submission speeds and compliance across various regions, ultimately facilitating quicker access to new therapies for patients.

Overview of Veeva RIM

Veeva RIM, part of the Veeva Development Cloud, comprises a suite of regulatory applications that empower companies by offering real-time visibility of their regulatory processes. Key components include Veeva Registrations, Veeva Submissions, Veeva Submissions Publishing, and Veeva Submissions Archive. These tools will help Servier in managing regulatory data, documents, and workflows more effectively than before.

Transformative Benefits

According to Alexandra Pearce, the global head of Worldwide Regulatory Affairs at Servier, implementing Veeva RIM will enable closer integration of data and processes, leading to enhanced operational efficiency. This transformation is crucial as it not only reduces the time required for submissions but also increases the overall transparency of operations. This is particularly important in the rapidly changing landscape of the European Union's regulatory requirements.

Moreover, the partnership with Veeva is expected to bolster Servier's capabilities, ensuring their teams are well-connected and able to respond quickly to evolving regulations. Paul Attridge, Veeva's Vice President of RIM strategy, emphasized Servier's commitment to digital innovation, noting that such advancements are essential for driving better regulatory oversight and for managing the challenges associated with rapid drug development and market entry.

Servier's Vision and Commitment

Servier, a prominent player in the biopharma space, specializes in therapeutic areas such as cardio-metabolism, oncology, and venous diseases. By adopting Veeva RIM, the company is taking significant strides towards transforming regulatory management and enhancing its drug delivery systems. This evolution not only positions Servier strategically in a competitive market but also reflects their dedication to improving patient outcomes through faster access to new medications.

As a global independent pharmaceutical company based in France, Servier stands firm in its mission to innovate and respond to healthcare needs. By leveraging Veeva's advanced platform, they aim to uphold their commitment to bringing effective treatments to patients more swiftly. This strategic alignment with Veeva marks a pivotal milestone in their operational methodology, aligning technology with timely patient care.

Conclusion

The adoption of Veeva RIM by Servier is a clear indication of the increasing importance of digital tools in the life sciences sector, particularly concerning regulatory compliance and operational efficiency. This partnership not only enhances Servier's internal capabilities but also signifies a broader trend within the industry towards embracing innovative solutions for managing regulatory complexities. With Veeva's support, Servier is poised for a more agile and efficient future, ultimately benefiting patients who rely on their therapies.

For more information about Veeva RIM and its applications, visit veeva.com/eu/VeevaRIM and engage with Veeva on their social media platforms for ongoing updates.